CRISPR Therapeutics shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 78 to 82.

CRISPR Therapeutics recently drew attention as updates highlighted progress in its gene-editing pipeline, including early-stage studies of CTX310, an in vivo therapy designed to lower LDL cholesterol ...

If you have been wondering whether CRISPR Therapeutics at around $57 a share is a bargain or a bubble, you are not alone. This stock sits at the crossroads of high science and high expectations. The ...

A recent study in the journal PNAS from the lab of Julie Overbaugh reveals a previously unknown antiviral function of a gene ...

CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...

Cathie Wood increased her Meta position in Q3 2025, adding about 791,000 shares. The move came after two quarters of selling, ...

Both stocks are risky, but one is far less so. This juicy upside potential comes at a cost. Investors seeking stocks with ...

Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine ...

Discover why Crispr Therapeutics AG is a strong buy with FDA-approved Casgevy, a promising pipeline, and major growth ...

Despite a challenging CASGEVY launch, high cash burn, and an almost 10% YTD share count growth, CRISPR’s pipeline breadth and ...

But sometimes, this top investor who focuses on innovation does see eye-to-eye with analysts, and the perfect example of this ...

Following the weekend data presentation, Citizens voiced optimism regarding CRISPR’s in-vivo projects. The firm noted some ...